

# Drug Utilization Review Board

(DUR Board)

Meeting – October 14, 2009 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

---

## AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. September 9, 2009 DUR Minutes – Vote
  - B. September 10, 2009 DUR Recommendation Memorandum
  - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review for June 2009
  - B. Retrospective Drug Utilization Review Response for May 2009
  - C. Medication Coverage Activity Audit for September 2009
  - D. Help Desk Activity Audit for September 2009

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman:

5. **Action Item - Vote to Prior Authorize Fibromyalgia Medications – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Otic Anti-Infectives – See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize New Narcotic Analgesic Medications – See Appendix E.**
  - A. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Plavix<sup>®</sup> and 30 Day Notice to Prior Authorize Effient<sup>™</sup> – See Appendix F.**
  - A. Current PA Criteria
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Topical Antiparasitics and 30 Day Notice to Prior Authorize Ulesfia<sup>™</sup> – See Appendix G.**
  - A. Current PA Criteria
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **Action Item – Annual Review of Hypnotic Medications and 30 Day Notice to Prior Authorize Edluar<sup>™</sup> and Intermezzo<sup>®</sup> – See Appendix H.**
  - A. Current PA Criteria
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
  - A. Please note that the November meeting will be held on Thursday, Nov. 12<sup>th</sup>.
  - B. Anxiolytic Criteria Review
  - C. Antiemetic Utilization Review
  - D. New Product Reviews
  - E. Annual Reviews

13. **Adjournment**